Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open- label extension study with optional narrow-band ultraviolet.

Slides:

Advertisements

Similar presentations

Treatment of generalized lichen nitidus with narrowband ultraviolet B Jae-Hong Park, MD, Yun-Lim Choi, MD, Won-Serk Kim, MD, Dong-Youn Lee, MD, Jun-Mo.

Advertisements

Use of the diagonal mattress suture to prevent dog-ear formation

Surgical margins for melanoma in situ

Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment Bong Kyun Ahn, MD, Byoung-Dae Kim, MD, Sang Ju Lee, MD, Seung.

Clavi syphilitici–an unusual presentation of syphilis

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

A girl with a solitary red bulla

Mary E. Logue, BA, Barrett J. Zlotoff, MD

Facial adenocarcinoma treated with intra-arterial chemotherapy

Striking leflunomide efficacy against refractory cutaneous sarcoidosis

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients Lucy Y. Liu, BA, Brittany.

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery

Baldness reversed by chemotherapy

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Sarah Sung, MD, Alexa B. Kimball, MD, MPH

María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo Stefan G. Vanderweil, MD, Shinya.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

JAK inhibitors in dermatology: The promise of a new drug class

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD

Assessing adherence with phototherapy protocols

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Pilot study of a skin cancer education curriculum for medical students

Applying for dermatology residency is difficult and expensive

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

Reply to: “A note on normality”

Google search trends for tanning salons: Temporal patterns indicate peak interest in mid spring Derek D. Reed, PhD, BCBA-D Journal of the American Academy.

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

Muhammed Razmi T, MD, DNB, Davinder Parsad, MD, Sendhil M. Kumaran, MD

Repigmentation of hair associated with melanoma in situ of scalp

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Infectious rash after riding elephants

Ethan T. Routt, BA, Jacob O. Levitt, MD

Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment Bong Kyun Ahn, MD, Byoung-Dae Kim, MD, Sang Ju Lee, MD, Seung.

Lip edema Journal of the American Academy of Dermatology

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Eva Wang, BS, John Koo, MD, Elie Levy, MD

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Melanocyte Regeneration in Vitiligo Requires WNT beneath their Wings

Hugh Gloster, MD, Chesahna Kindred, MBA

Medicaid acceptance among pediatric dermatologists

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Penile calciphylaxis Journal of the American Academy of Dermatology

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Yu-Chen Huang, MD, Ying-Chih Cheng, MD

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Gordon W. Jung, MD, Patricia T. Ting, MSc, MD, Thomas G

Michelle A. Pipitone, MD, Brian Adams, MD, MPH, Anita Sheth, MD, T

A simple algorithm for evaluating dermatologic disease in critically ill patients: A study based on retrospective review of medical intensive care unit.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA) John E. Harris, MD, PhD, Mehdi Rashighi,

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

A grayscale photograph with high dynamic range taken under a Wood's lamp for better recognition of vitiligo lesions Jung Min Bae, MD, PhD, Tae Young.

Numerous hyperpigmented macules of the oral mucosa

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Comment on “Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control.

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Orit Kaidar-Person, MD, Ayelet Eran, MD, Gil Bar-Sela, MD

Photosensitive lichenoid drug eruption to capecitabine

Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment Michael.

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Presentation transcript:

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open- label extension study with optional narrow-band ultraviolet B Deep Joshipura, MD, Abdulaziz Alomran, MD, Pedro Zancanaro, MD, David Rosmarin, MD Journal of the American Academy of Dermatology Volume 78, Issue 6, Pages 1205-1207.e1 (June 2018) DOI: 10.1016/j.jaad.2018.02.023 Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Mean percent improvement of VASI score for total, facial, acral, truncal, and nonacral extremities from baseline to week 52 for all enrolled patients with vitiligo (n = 8). Data from their last recorded visit were used for patients (n = 3) who dropped out of the study. Phototherapy was permitted after week 20 (bold black arrow). VASI, Vitiligo Area Scoring Index. Journal of the American Academy of Dermatology 2018 78, 1205-1207.e1DOI: (10.1016/j.jaad.2018.02.023) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Repigmentation noted on truncal and nonacral extremities after twice-daily topical ruxolitinib application at baseline, week 20 (without phototherapy), and week 52 (with phototherapy) in 2 vitiligo patients after combination narrow band ultraviolet B. Journal of the American Academy of Dermatology 2018 78, 1205-1207.e1DOI: (10.1016/j.jaad.2018.02.023) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions